Kids with deadliest brain cancers survive years after breakthrough cell therapy

Key Points:

• A new T-cell immunotherapy shows promise in treating pediatric brain tumors, which are the leading cause of cancer-related deaths in children, by training the immune system to target and destroy cancer cells.
• Unlike previous T-cell therapies effective mainly against blood cancers, this treatment targets multiple proteins (WT1, PRAME, Survivin) commonly found in pediatric brain tumors, improving the chances of eliminating the cancer and preventing relapse.
• The therapy overcomes challenges posed by the blood-brain barrier and tumor heterogeneity, offering a potentially safer and less aggressive alternative to chemotherapy with preserved quality of life for patients.
• The initial human trial demonstrated safety, feasibility, and early anti-tumor responses, with some patients remaining disease-free years after treatment, marking a significant breakthrough in pediatric cancer research.
• Researchers plan to advance to a Phase 2 trial to further evaluate the treatment’s effectiveness and move toward FDA approval, aiming to expand access to this innovative therapy for children with aggressive brain cancers.